<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kang, Yoon-Koo</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">A Randomized Phase 3 Trial of Intraperitoneal Cisplatin and Early Mitomycin C plus Long-Term Doxifluridine plus Cisplatin versus Mitomycin C plus Short-Term Doxifluridine</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">In patients with grossly serosa-positive advanced gastric cancer, postoperative adjuvant chemotherapy with intraperitoneal cisplatin and early mitomycin C (M) plus long-term doxifluridine plus cisplatin (iceMFP) improved recurrence-free and overall survival. The comparator regimen in the phase 3 trial [AMC 0101] was M plus short-term doxifluridine.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>